Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab
Status:
Recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety, tolerability and preliminary antitumor
activity of ZW25 in combination with docetaxel in participants with human epidermal growth
factor receptor 2 (HER2)-positive breast cancer, and ZW25 in combination with tislelizumab
and chemotherapy in participants with HER2-positive gastric/gastroesophageal Junction (GEJ)
adenocarcinoma